FdaApplication
NDA 215515
Identifiers
- fda_app_no: NDA215515
Properties
| Property | Value |
|---|---|
| applicant_name | ALNYLAM PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2022-06-13 |
Revenue by product
AMVUTTRA
| Period | Revenue |
|---|---|
| Q2 2026 | $1.0B |
| Q1 2026 | $889.9M |
| Q3 2025 | $685.3M |
| Q2 2025 | $492.0M |
| Q1 2025 | $310.0M |
| Q4 2024 | $286.5M |
| Q3 2024 | $258.6M |
| Q2 2024 | $230.1M |
| Q1 2024 | $195.2M |
| Q4 2023 | $175.3M |
| Q3 2023 | $148.7M |
| Q2 2023 | $132.1M |
| Q1 2023 | $101.8M |
| Q4 2022 | $68.6M |
| Q3 2022 | $25.2M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| AMVUTTRA | VUTRISIRAN SODIUM | EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML) | SOLUTION;SUBCUTANEOUS |
1 product